Most Popular

Tesla (NASDAQ:TSLA) Q4 Earnings Preview Anticipation Builds as Tesla Prepares to Release Q4 Earnings

Tesla (NASDAQ:TSLA) is gearing up to reveal its financial results for the fourth quarter of 2023 on Wednesday, January 24. The electric vehicle (EV) giant is expected to see a boost in top-line growth due to higher deliveries, while the bottom line may face pressure …

Read more

Procter & Gamble Impresses with Margin Growth in FQ2 Procter & Gamble Impresses with Margin Growth in FQ2

SOPA Images/LightRocket via Getty Images Procter & Gamble Company (NYSE:PG) saw an uptick in early trading on Tuesday after unveiling a FQ2 earnings report that left investors with mixed sentiments. The company’s organic sales rose 4% during the quarter— a slightly shy of the +4.6% …

Read more

Insight into Beyond Meat’s Options Market Insight into Beyond Meat’s Options Market

Benzinga’s options scanner just discovered over 9 options trades for Beyond Meat BYND, totaling $459,745. Simultaneously, our algo intercepted 7 trades, amounting to $442,745 in total. Insights into Price Target Taking into account the Volume and Open Interest on these contracts, it seems that whales …

Read more

Investment News: Stocks with Great Relative Strength Investment News: Stocks with Great Relative Strength

High-Performing Stocks Near 52-Week Highs As the market reflects positive momentum, a number of stocks are either approaching or surpassing their 52-week highs. Among these, renowned names such as Amazon (AMZN), Arista Networks (ANET), and Abercrombie & Fitch (ANF) have demonstrated exceptional performance against the …

Read more

Pfizer, Autodesk, and AbbVie in Focus Investment Insights: Pfizer, Autodesk, and AbbVie in Focus

On CNBC’s “Halftime Report Final Trades,” Liz Young of BNY Mellon Investment Management named Health Care Select Sector SPDR Fund XLV as her final trade. Joshua Brown of Ritholtz Wealth Management picked Pfizer Inc. PFE, which bottomed in the middle of December. At the JPMorgan …

Read more

Breaking Ground: First Wave BioPharma Primed for Phase 3 Clinical TrialsBreaking Ground: First Wave BioPharma Primed for Phase 3 Clinical Trials

Company Vision During a recent appearance on Benzinga’s All-Access, James Sapirstein, Chairman, President & CEO of First Wave BioPharma, Inc. (NASDAQ:FWBI) shared insights about the company’s mission. First Wave BioPharma is a clinical-stage biopharmaceutical company with a dedicated focus on developing targeted, non-systemic therapies for …

Read more

Market Watch: Goldman Sachs and Home Depot Lead the Dow Market Watch: Goldman Sachs and Home Depot Lead the Dow

Goldman Sachs Group During early trading on Monday, the shares of Goldman Sachs Group have risen by 2.1%, making it the best performing stock among the Dow Jones Industrial Average components. Year to date, the financial giant has secured a 1.2% gain, demonstrating resilience amidst …

Read more

The Rise of Illinois Tool Works: A Dividend King’s Triumph and Potential

Established companies that have a whopping 50 years of dividend history under their belt are known as Dividend Kings, a testament to their remarkable consistency in both performance and earnings growth. Many of these Kings are traditional industry leaders found in more stable sectors such …

Read more

Virgin Galactic Stock Analysis Virgin Galactic: Can the Stock Reach New Heights?

The price roller-coaster ride of Virgin Galactic Holdings (SPCE) has been nothing short of a wild intergalactic adventure for shareholders. Soaring from $7.29 in December 2019 to over $50 in June 2021, the stock has now dipped to $2.04, valuing the company at $767 million …

Read more

Is Now the Time to Invest in Nvidia as Shares Approach $600? Is Now the Time to Invest in Nvidia as Shares Approach $600?

Nvidia NVDA, one of the top performers in 2024, has seen its shares soar over +200% in the last year, outperforming the broader market. With Nvidia’s stock currently hitting new 52-week highs of $595 and closing today’s trading session up +4%, the chipmaker is on …

Read more